Home › Funds › ADAR1 Capital Management, LLC › TSHA
ADAR1 Capital Management, LLC position in TSHA
TAYSHA GENE THERAPIES INC · Health Care
ADAR1 Capital Management, LLC reported holding 3,040,466 shares of TSHA (TAYSHA GENE THERAPIES INC) in its Q2 2026 13F filing — a position valued at US$20.7M, representing 1.15% of its reported portfolio and ranking #19 among its reported holdings. ADAR1 Capital Management, LLC has disclosed TSHA holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ADAR1 Capital Management, LLC's TSHA position evolved
ADAR1 Capital Management, LLC first disclosed a stake in TSHA in Q4 2023 at 209,000 shares (US$370K). The position peaked in Q2 2026 at 3,040,466 shares, worth US$20.7M. Across 11 filings, ADAR1 Capital Management, LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 3,040,466 shares valued at US$20.7M — an increase of 61,037 shares quarter over quarter.. Notable position changes include a 477% increase in Q2 2024 (shares fell 10% over the following quarter), a 500% increase in Q1 2025 (shares rose 66% over the following quarter), a 182% increase in Q2 2025 (shares rose 42% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 209.00K | $369.93K | New |
| Q1 2024 | 43.50K | $124.84K | Reduce |
| Q2 2024 | 250.80K | $561.79K | Add |
| Q3 2024 | 251.40K | $505.31K | Hold |
| Q4 2024 | 177.71K | $307.43K | Reduce |
| Q1 2025 | 1.07M | $1.48M | Add |
| Q2 2025 | 3.01M | $6.95M | Add |
| Q3 2025 | 2.84M | $9.27M | Reduce |
| Q4 2025 | 2.50M | $13.73M | Reduce |
| Q1 2026 | 2.98M | $13.32M | Add |
| Q2 2026 | 3.04M | $20.71M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TSHA and 13F data
TSHA (TAYSHA GENE THERAPIES INC) is a Health Care company. 56 other funds we track also report a position in TSHA — the largest reported positions include Avoro Capital Advisors LLC (US$162.7M), RA CAPITAL MANAGEMENT, L.P. (US$160.4M), Vestal Point Capital, LP (US$132.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TSHA
- Avoro Capital Advisors LLC 23.89M sh · $162.68M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 23.56M sh · $160.41M · Q2 2026
- Vestal Point Capital, LP 19.41M sh · $132.22M · Q2 2026
- RTW INVESTMENTS, LP 13.56M sh · $92.35M · Q2 2026
- Siren, L.L.C. 9.85M sh · $67.06M · Q2 2026
- Octagon Capital Advisors LP 9.69M sh · $66.01M · Q2 2026
- MPM BioImpact LLC 4.50M sh · $30.64M · Q2 2026
- BAKER BROS. ADVISORS LP 4.00M sh · $27.27M · Q2 2026
- GordonMD Global Investments LP 723.18K sh · $24.50M · Q2 2026
- Casdin Capital 3.25M sh · $22.13M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 1.99M sh · $13.57M · Q2 2026
- B Group, Inc. 1.80M sh · $12.26M · Q2 2026
More on ADAR1 Capital Management, LLC
FAQ
How long has ADAR1 Capital Management, LLC held TSHA?
ADAR1 Capital Management, LLC has disclosed TSHA holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is ADAR1 Capital Management, LLC's current position in TSHA?
As of Q2 2026, ADAR1 Capital Management, LLC holds 3.04M shares of TSHA (TAYSHA GENE THERAPIES INC), valued at $20.71M, representing 1.15% of its reported portfolio and ranking #19.
Has ADAR1 Capital Management, LLC been buying or selling TSHA?
In the latest 13F filing (Q2 2026), ADAR1 Capital Management, LLC increased its position in TSHA. The position peaked in Q2 2026 at 3.04M shares.
Which other funds hold TSHA?
Other major institutional holders of TSHA include Avoro Capital Advisors LLC, RA CAPITAL MANAGEMENT, L.P., Vestal Point Capital, LP, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.